PremiumRatingsCautious Hold on Bolt Biotherapeutics Amid Awaited Phase 1 Data and Strategic Decisions Cautious Hold Rating on Bolt Biotherapeutics Amid Promising Clinical Data and Financial Uncertainty Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel PremiumThe FlyBolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting Cautious Hold Rating for Bolt Biotherapeutics Amidst Promising Developments and Uncertainties PremiumPre-EarningsBOLT Earnings this Week: How Will it Perform? Bolt Biotherapeutics provides update on co-development collaboration with Toray Bolt Biotherapeutics Announces Board Changes and Appointments